BLLN

Business Context and Reporting Period

BillionToOne, Inc. (BLLN) is a precision diagnostics company utilizing a single-molecule next-generation sequencing (smNGS) platform for prenatal and oncology testing. This Form 10-Q covers the quarterly period ended March 31, 2026. The company is classified as an emerging growth company and a non-accelerated filer.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 84% year-over-year, driven by a 44% increase in delivered test volume (188,000 tests vs. 131,000) and a 28% increase in Average Selling Price (ASP). New payor agreements contributed $9.2 million in revenue related to prior period performance obligations.
• Profitability: The company achieved a net income of $18.0 million compared to a net loss of $4.0 million in the prior year. Operating income turned positive at $17.8 million from a loss of $2.3 million.
• Debt Financing: Long-term debt increased by $32.8 million due to the mandatory draw of the third tranche ($30.0 million) under the Oberland Capital Note Purchase Agreement on March 31, 2026, triggered by meeting revenue and gross margin thresholds.
• Expenses: Operating expenses rose 52% to $61.3 million, primarily due to increased headcount in sales (SG&A) and R&D to support commercial expansion and product innovation.

Outlook, Risks, and Management Commentary

• Product Pipeline: Management highlighted the launch of Unity Confirm (May 2026) for non-invasive confirmation of high-risk prenatal results and new oncology applications (Northstar PGx and Northstar Select CH). A tissue-free, pan-cancer Minimal Residual Disease (MRD) test is expected in Q4 2026.
• Strategic Partnerships: The company continues its partnership with Johnson & Johnson for clinical trial support and companion diagnostic development. Remaining performance obligations for contracts exceeding one year were approximately $7.6 million as of March 31, 2026.
• Liquidity: With $537.5 million in cash and positive operating cash flow, management believes current resources are sufficient to fund operations for at least the next 12 months.
• Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of March 31, 2026, due to unremediated material weaknesses in the control environment, financial instrument accounting, and user access controls. Remediation efforts are ongoing.
• Risks: Key risks include dependence on third-party payor reimbursement (over 90% of revenue), the ability to maintain gross margins as test volumes grow, and the successful execution of clinical trials and regulatory approvals.

Investor Verification Checklist

• Reimbursement Sustainability: Verify the durability of the 28% ASP increase and the impact of new payor contracts on future collections, given that over 90% of revenue relies on third-party payors.
• Debt Covenants: Monitor compliance with the Oberland Capital revenue covenants, which require trailing six-month net revenue to reach $120.0 million by Q4 2026 and a gross margin of at least 30%.
• Internal Control Remediation: Assess the timeline and progress for remediating the material weaknesses in internal controls over financial reporting, which currently render disclosure controls ineffective.
• Valuation Allowance: Watch for the potential release of the valuation allowance on deferred tax assets, which management expects may occur prior to December 31, 2026, contingent on sustained profitability.
• Non-GAAP Reconciliations: Review the reconciliation of GAAP Net Income to Adjusted EBITDA ($26.0 million) and Non-GAAP Net Income ($28.4 million) to understand the impact of fair value adjustments on debt and warrants.